Biocure Technology Inc. (CSE:CURE, OTCQB:BICTF) (“CURE” or the “Company”) is pleased to announce that it has arranged a non-brokered private placement of 6,976,745 million units at 43 cents per unit for gross proceeds of $3 Million or more, depending on investor interest.
Biocure Technology Inc. (CSE:CURE, OTCQB:BICTF) (“CURE” or the “Company”) is pleased to announce that it has arranged a non-brokered private placement of 6,976,745 million units at 43 cents per unit for gross proceeds of $3 Million or more, depending on investor interest. Each Unit will entitle the holder to receive one common share of the Company (each a “Common Share”) and one Full Warrant (“Warrants”) exercisable for 24 Months for CDN$0.86. Each warrant is subject to accelerated expiry provisions, such that if at any time after the expiry of any resale restriction governing the subscribed shares, the corporation’s common shares trade on the Canadian Securities Exchange at or above a volume-weighted average trading price of $1.29 per common share for 10 consecutive trading days, the company may give notice to the holders that each warrant will expire 30 days from the date of providing such notice.
Finder’s fees or commissions may be payable by the Company in connection with this Private Placement.
The net proceeds from the non-brokered private placement are intended to be used for general working capital and research and development.
Biocure is a South Korean based Bio Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. Biocure is in the process of pre- clinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, PEG- Filgrastim and Ranibizumab as well as CAR-T Cell Therapy. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis (“MS”) Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes. Biocure is also developing a foot and mouth disease vaccine, and a hair growth production product.
ON BEHALF OF THE BOARD OF DIRECTORS
/S/ “SANG MOK LEE”
CEO and Director
For further information, please contact:
Biocure Technology Inc. Telephone: 604-609-7146, or
Certain statements in this news release, which are not historical in nature, constitute “forward looking statements” within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company’s proposed activities under the Agreement and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management’s current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements. Neither the Canadian Securities Exchange (the “CSE”) nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.